High-throughput sequencing analysis of a "hit and run" cell and animal model of KSHV tumorigenesis.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
13
11
2019
accepted:
30
04
2020
revised:
13
07
2020
pubmed:
1
7
2020
medline:
11
8
2020
entrez:
1
7
2020
Statut:
epublish
Résumé
Kaposi's sarcoma (KS), is an AIDS-associated neoplasm caused by the KS herpesvirus (KSHV/ HHV-8). KSHV-induced sarcomagenesis is the consequence of oncogenic viral gene expression as well as host genetic and epigenetic alterations. Although KSHV is found in all KS-lesions, the percentage of KSHV-infected (LANA+) spindle-cells of the lesion is variable, suggesting the existence of KS-spindle cells that have lost KSHV and proliferate autonomously or via paracrine mechanisms. A mouse model of KSHVBac36-driven tumorigenesis allowed us to induce KSHV-episome loss before and after tumor development. Although infected cells that lose the KSHV-episome prior to tumor formation lose their tumorigenicity, explanted tumor cells that lost the KSHV-episome remained tumorigenic. This pointed to the existence of virally-induced irreversible oncogenic alterations occurring during KSHV tumorigenesis supporting the possibility of hit and run viral-sarcomagenesis. RNA-sequencing and CpG-methylation analysis were performed on KSHV-positive and KSHV-negative tumors that developed following KSHV-episome loss from explanted tumor cells. When KSHV-positive cells form KSHV-driven tumors, along with viral-gene upregulation there is a tendency for hypo-methylation in genes from oncogenic and differentiation pathways. In contrast, KSHV-negative tumors formed after KSHV-episome loss, show a tendency towards gene hyper-methylation when compared to KSHV-positive tumors. Regarding occurrence of host-mutations, we found the same set of innate-immunity related mutations undetected in KSHV-infected cells but present in all KSHV-positive tumors occurring en exactly the same position, indicating that pre-existing host mutations that provide an in vivo growth advantage are clonally-selected and contribute to KSHV-tumorigenesis. In addition, KSHV-negative tumors display de novo mutations related to cell proliferation that, together with the PDGFRAD842V and other proposed mechanism, could be responsible for driving tumorigenesis in the absence of KSHV-episomes. KSHV-induced irreversible genetic and epigenetic oncogenic alterations support the possibility of "hit and run" KSHV-sarcomagenesis and point to the existence of selectable KSHV-induced host mutations that may impact AIDS-KS treatment.
Identifiants
pubmed: 32603362
doi: 10.1371/journal.ppat.1008589
pii: PPATHOGENS-D-19-02123
pmc: PMC7357787
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1008589Subventions
Organisme : NIAID NIH HHS
ID : P30 AI073961
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA136387
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA221208
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS Pathog. 2010 Jun 03;6(6):e1000935
pubmed: 20532208
Cell Host Microbe. 2011 Dec 15;10(6):577-90
pubmed: 22177562
Trends Microbiol. 2010 Oct;18(10):439-47
pubmed: 20724161
Cancer Lett. 2011 Jun 28;305(2):200-17
pubmed: 20813452
Cancer Res. 2012 Mar 1;72(5):1157-69
pubmed: 22237624
Virus Genes. 2003 Dec;27(3):237-47
pubmed: 14618084
Proc Natl Acad Sci U S A. 2009 May 26;106(21):8683-8
pubmed: 19429708
PLoS Pathog. 2019 Dec 27;15(12):e1008221
pubmed: 31881074
Nat Genet. 2007 Feb;39(2):232-6
pubmed: 17200670
Cancer Res. 2018 Jan 1;78(1):230-245
pubmed: 29066510
Anticancer Res. 1994 May-Jun;14(3A):921-6
pubmed: 8074494
J Infect Dis. 2012 Apr 1;205(7):1095-9
pubmed: 22357696
PLoS Pathog. 2018 Jul 9;14(7):e1007175
pubmed: 29985958
Cancer Res. 2001 Nov 15;61(22):8171-8
pubmed: 11719447
J Exp Med. 2000 Feb 7;191(3):417-22
pubmed: 10662787
N Engl J Med. 2005 Mar 31;352(13):1317-23
pubmed: 15800227
Semin Immunopathol. 2020 Apr;42(2):143-157
pubmed: 32219477
J Virol. 2011 May;85(9):4612-7
pubmed: 21307197
Genome Res. 2014 Feb;24(2):177-84
pubmed: 24068705
Cell. 1981 Apr;24(1):33-40
pubmed: 6263490
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nucleic Acids Res. 2001 Apr 1;29(7):1410-9
pubmed: 11266540
Cancer Cell. 2007 Mar;11(3):245-58
pubmed: 17349582
Curr Biol. 1999 Jan 28;9(2):105-8
pubmed: 10021369
Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11
pubmed: 16341240
J Virol. 2016 Sep 12;90(19):8822-41
pubmed: 27466416
J Clin Invest. 2016 Sep 1;126(9):3165-75
pubmed: 27584730
Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14554-9
pubmed: 16983096
Nat Rev Dis Primers. 2019 Jan 31;5(1):9
pubmed: 30705286
Nat Microbiol. 2019 Jan;4(1):164-176
pubmed: 30420784
Antioxid Redox Signal. 2013 Jan 1;18(1):80-90
pubmed: 22746102
AIDS. 2008 May 11;22(8):937-45
pubmed: 18453853
J Clin Invest. 2010 Apr;120(4):939-49
pubmed: 20364091
J Clin Invest. 2004 Jan;113(1):124-36
pubmed: 14702116
Nat Med. 2003 Mar;9(3):300-6
pubmed: 12592400
J Gen Virol. 2010 Sep;91(Pt 9):2176-85
pubmed: 20573854
Science. 1985 Apr 12;228(4696):187-90
pubmed: 2579435
Cancer Res. 1993 Nov 1;53(21):5079-82
pubmed: 8221638
J Virol. 2018 Jul 31;92(16):
pubmed: 29899086
Cell Host Microbe. 2014 Mar 12;15(3):266-82
pubmed: 24629334
Cell. 2007 Sep 7;130(5):851-62
pubmed: 17803908
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Semin Cancer Biol. 2009 Dec;19(6):366-76
pubmed: 19635566
Cancer Res. 2006 Jan 1;66(1):168-74
pubmed: 16397229
Hum Mol Genet. 2000 Oct;9(16):2395-402
pubmed: 11005794
Cell. 1990 Aug 10;62(3):503-14
pubmed: 1974172
Nature. 1998 Jan 1;391(6662):86-9
pubmed: 9422510
J Clin Oncol. 2014 Feb 10;32(5):402-8
pubmed: 24378417
Pathol Oncol Res. 1999;5(1):17-20
pubmed: 10079372
PLoS Pathog. 2014 Jan;10(1):e1003847
pubmed: 24453964
Nat Methods. 2013 Nov;10(11):1081-2
pubmed: 24037244
Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4119-24
pubmed: 11274437
Nat Rev Cancer. 2010 Oct;10(10):707-19
pubmed: 20865011
J Virol. 2004 Oct;78(20):11108-20
pubmed: 15452231
J Clin Oncol. 2016 Dec;34(34):4125-4131
pubmed: 27863194
PLoS Pathog. 2014 Jul 10;10(7):e1004154
pubmed: 25010730